NCT03867617

Cell Therapy for Immunomodulation in Kidney Transplantation

A Prospective Controlled Trial to Evaluate Safety and Efficacy of in Vitro Expanded Recipient Regulatory T Cell Therapy and Tocilizumab Together With Donor Bone Marrow Infusion in HLA-mismatched Living Donor Kidney Transplant Recipients

• Status: Active Not Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Thomas Wekerle · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study investigates treatment with recipient regulatory T cells and donor bone marrow together with tocilizumab for immunomodulation in living donor kidney transplant recipients.

Conditions

• Kidney Transplantation

Interventions

Type	Name	Description
OTHER	Regulatory T cells	Single infusion of expanded regulatory T cells.
DRUG	Tocilizumab	Treatment during first month post-transplant.
OTHER	Bone marrow	Infusion of donor bone marrow cells.
PROCEDURE	Kidney transplant	Living donor kidney transplantation.
OTHER	Immunosuppressive drug therapy	Immunosuppressive drug therapy.

Timeline

• Start date: 2019-08-01
• Primary completion: 2024-06-30
• Completion: 2028-06-01
• First posted: 2019-03-08
• Last updated: 2024-12-02

Locations

1 site across 1 country: Austria